Patents by Inventor ALLEN C. GAO

ALLEN C. GAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOENGINEERED WNT5A THERAPEUTICS FOR ADVANCED CANCERS
    Publication number: 20230407297
    Abstract: The present disclosure provides methods and compositions for inhibiting Wnt5a expression in cells such as prostate cancer cells.
    Type: Application
    Filed: November 3, 2021
    Publication date: December 21, 2023
    Applicants: The Regents of the University of California, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Allen C. Gao, Aiming Yu
  • DUAL ANDROGEN RECEPTOR/AKR1C3 INHIBITORS
    Publication number: 20230022235
    Abstract: The present invention provides benzamide compounds, compositions containing the benzamides, and use of the benzamides for inhibiting androgen receptor (AR) and/or aldo-keto reductase family 1 member C3 (AKR1C3). Also described herein methods for the treatment of hormone-mediated diseases and conditions, including hormone-related cancers such as castration resistant prostate cancer.
    Type: Application
    Filed: May 16, 2022
    Publication date: January 26, 2023
    Applicants: The Regents of the University of California, Ohio State Innovation Foundation, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Allen C. Gao, Pui-Kai Li, Enming Xing, Xiaolin Cheng, Xiaotian Kong, Wei Lou
  • Treatment of metastatic prostate cancer
    Patent number: 11215617
    Abstract: The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: January 4, 2022
    Assignees: The Regents of the University of California, U.S. Government Represented by the Department of Veterans Affairs
    Inventors: Allen C. Gao, Chengfei Liu, Wei Lou, Chong-xian Pan
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF ANDROGEN-MEDIATED DISEASE
    Publication number: 20210253628
    Abstract: Provided herein are steroid sulfatase inhibitor compounds and androgen receptor inhibitor compounds that can be useful in, for example, the treatment of cancers such as prostate cancer and breast cancer. Pharmaceutical compositions and kits including the compounds are described, as well as methods for the treatment of cancer such as prostate cancer and breast cancer.
    Type: Application
    Filed: April 29, 2021
    Publication date: August 19, 2021
    Applicants: The Regents of the University of California, Ohio State Innovation Foundation
    Inventors: Allen C. Gao, Pui-Kai Li
  • TREATMENT OF METASTATIC PROSTATE CANCER
    Publication number: 20200041516
    Abstract: The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7.
    Type: Application
    Filed: October 16, 2019
    Publication date: February 6, 2020
    Applicants: The Regents of the University of California, U.S. Government represented by the Department of Veterans Affairs
    Inventors: Allen C. Gao, Chengfei Liu, Wei Lou, Chong-xian Pan
  • COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
    Publication number: 20180153850
    Abstract: Methods and compositions are provided for treatment of cancer, including prostate cancer. In one aspect, the present invention provides a composition comprising a taxane and a drug that reduces efflux of the taxane from a cell. The drug that reduces efflux of the taxane can be an inhibitor of ABCB1 efflux activity. In some cases, the inhibitor of ABCB1 efflux activity is an inhibitor of ABCB1 ATPase activity selected from the group consisting of enzalutamide and bicalutamide.
    Type: Application
    Filed: October 27, 2017
    Publication date: June 7, 2018
    Applicant: The Regents of the University of California
    Inventors: Allen C. Gao, Yezi Zhu
  • TREATMENT OF METASTATIC PROSTATE CANCER
    Publication number: 20170315127
    Abstract: The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7.
    Type: Application
    Filed: April 20, 2016
    Publication date: November 2, 2017
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: ALLEN C. GAO, CHENGFEI LIU, WEI LOU, Chong-xian Pan